Login
From:
Cancer Network
(Uncensored)
subscribe
ODAC Votes Against PD-L1 as Efficacy Biomarker in Gastric Cancers
https://www.cancernetwork.com/view/odac-votes-against-pd-l1-as-efficacy-biomarker-in-gastric-cancers
links
backlinks
Roast topics
Find topics
Find it!
Ten votes were cast against PD-L1 as an efficacy biomarker for therapies intended to treat patients with gastric or GEJ adenocarcinoma.
